A case of rapid desensitization for rituximab-induced delayed hypersensitivity reaction
Allergy, Asthma & Respiratory Disease
; : 109-112, 2019.
Article
Dans Ko
| WPRIM
| ID: wpr-739510
Responsable en Bibliothèque :
WPRO
ABSTRACT
Rituximab is a monoclonal antibody used for the treatment of B-cell malignancies, including diffuse large B-cell lymphoma. Infusion-related hypersensitivity reactions to rituximab is well known, and delayed hypersensitivity reactions to rituximab are also reported. Desensitization is commonly used to prevent immediate hypersensitivity reactions, but recently there have been cases of successful desensitization therapy for delayed hypersensitivity reactions. A 66-year-old patient who underwent rituximab treatment for diffuse large B-cell lymphoma showed repeated rituximab-induced delayed hypersensitivity reactions with whole body rashes. Intravenous rapid desensitization was performed by using a 1-bottle, 11-step protocol for 6 cycles and thereafter hypersensitivity reaction did not recur. We herein reported a case of delayed hypersensitivity reaction caused by rituximab, which was successfully desensitized using our 11-step protocol.
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Lymphocytes B
/
Lymphome B
/
Désensibilisation immunologique
/
Exanthème
/
Rituximab
/
Hypersensibilité
/
Hypersensibilité retardée
/
Hypersensibilité immédiate
Type d'étude:
Guideline
Limites du sujet:
Aged
/
Humans
langue:
Ko
Texte intégral:
Allergy, Asthma & Respiratory Disease
Année:
2019
Type:
Article